Kymera Therapeutics (KYMR) furnishes quarterly results press release for Sept. 30, 2025

Rhea-AI Filing Summary

Kymera Therapeutics, Inc. filed a current report to note that it announced its financial results for the quarter ended September 30, 2025. The company is furnishing, as an exhibit, a press release that provides details on its results of operations and financial condition for that quarter.

The report clarifies that the press release and related information are being furnished rather than filed under securities laws, which affects how they are treated for certain legal liability and incorporation-by-reference purposes.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001815442false00018154422025-11-042025-11-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 4, 2025

KYMERA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-39460		81-2992166
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

Kymera Therapeutics, Inc.

500 North Beacon Street, 4th Floor

Watertown, Massachusetts 02472

(Address of principal executive offices, including zip code)

(857) 285-5300

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trade Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	KYMR	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition

On November 4, 2025, Kymera Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.

The information in this Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Exhibits

(d) Exhibits

Exhibit No.		Description
99.1		Press release issued by Kymera Therapeutics, Inc. on November 4, 2025, furnished herewith.
104		Cover Page Interactive Data

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		Kymera Therapeutics, Inc.
Date: November 4, 2025		By:		/s/ Nello Mainolfi
				Nello Mainolfi, Ph.D.
				President and Chief Executive Officer

FAQ

What did Kymera Therapeutics (KYMR) disclose in this 8-K filing?

Kymera Therapeutics disclosed that it announced its financial results for the quarter ended September 30, 2025. The company furnished a press release as an exhibit, providing more detail on its results of operations and financial condition for that period.

Which period’s results are covered in Kymera Therapeutics’ (KYMR) latest update?

The update covers Kymera Therapeutics’ financial results for the quarter ended September 30, 2025. These results are described in a press release dated November 4, 2025, which is attached to the report as Exhibit 99.1 for investors and analysts to review.

How did Kymera Therapeutics (KYMR) provide its quarterly financial details?

Kymera Therapeutics provided its quarterly financial details through a press release. That press release, dated November 4, 2025, is furnished as Exhibit 99.1 to the current report and contains information on the company’s results of operations and financial condition.

Is the Kymera Therapeutics (KYMR) earnings press release considered filed with the SEC?

No. Kymera Therapeutics states that the press release and related information are being furnished, not filed, under the Exchange Act. This means they are not subject to certain Section 18 liabilities or automatically incorporated into other securities law filings.

Which exhibit in the Kymera Therapeutics (KYMR) 8-K contains the financial results press release?

Exhibit 99.1 contains the press release with Kymera Therapeutics’ financial results. The exhibit is described as a press release issued on November 4, 2025, providing details on the company’s results of operations and financial condition for the relevant quarter.

Who signed the Kymera Therapeutics (KYMR) current report covering the quarterly results?

The current report was signed on behalf of Kymera Therapeutics by Nello Mainolfi, Ph.D. He is identified as the company’s President and Chief Executive Officer, acting as the duly authorized officer for the registrant in this filing.